Combined use of a somatostatin analog and a dopamine agonist for treatment of CD has been proposed on the basis of similar studies suggesting additive effects on growth hormone secretion from somatotroph adenomas [60]. This evidence concerns the gene GH1 and growth hormone secreting pituitary adenoma 1.